#United States #Acquisition #Stamford #Aurora Cannabis #Curaleaf

Curaleaf Receives Competition Law Approvals for Aurora Cannabis Acquisition

Curaleaf Holdings, a prominent player in the cannabis sector, has successfully navigated the regulatory waters required for its planned acquisition of Aurora Cannabis. With regulatory approvals now in hand from key jurisdictions including Germany and Canada, Curaleaf is poised to advance its strategic acquisition plans.

The Acquisition Overview

As of November 10, 2026, Curaleaf reported that it has secured all necessary competition law clearances, primarily from Germany's Federal Ministry for Economic Affairs and Energy and Canada's Competition Bureau. These clearances are critical as they represent the final regulatory hurdles to be cleared for the acquisition of Aurora Cannabis Inc.

Specifically, on October 20, 2026, the German authorities granted permission for Curaleaf to acquire 100% of the voting rights in various Aurora entities, including Aurora Europe GmbH, Aurora Deutschland GmbH, and Aurora Produktions GmbH. Then, shortly thereafter, Canada’s Competition Bureau issued a no-action letter, indicating that they would not challenge the acquisition under their competition laws.

Impact on Shareholders and Market Position

The confirmation from Germany's Federal Cartel Office further solidifies Curaleaf's strategic move, clarifying that the acquisition does not meet any prohibitory conditions under German competition law. With all the appropriate clearances diligently secured, Boris Jordan, the Chairman and CEO of Curaleaf, expressed optimism about the trajectory of the acquisition. He stated, “With all required competition law clearances secured, the path is clear for Aurora shareholders to realize the value our Offer provides.”

This acquisition is significant not just for Curaleaf but also for Aurora shareholders, as it potentially offers them a substantial exit opportunity and an enhanced bid from Curaleaf, which was originally announced on October 6, 2026. The acquisition will allow Curaleaf to consolidate its market position and expand its footprint in the global cannabis sector, further catering to both consumer and medical cannabis markets.

Future Steps Before Finalization

Curaleaf's offer will remain on the table until December 4, 2026, unless it decides otherwise. With the regulatory clearance achieved, attention turns to remaining conditions tied to the Offer. Curaleaf emphasizes the importance of these clearances in bolstering its proposal, providing adequate certainty to complete the deal swiftly. In this competitive landscape, Curaleaf is urging Aurora shareholders to weigh the advantages presented by their offer against alternatives, particularly as Organigram’s competing acquisition proposal must still navigate through additional shareholder and regulatory complexities.

Conclusion

The successful acquisition of Aurora Cannabis by Curaleaf signals a pivotal shift in the cannabis landscape as consolidation intensifies within the industry. With the regulatory bodies approving key steps in the acquisition process, Curaleaf seems well-positioned to capitalize on market potentials and enhance shareholder value. Both companies’ future will be closely observed as they navigate the finalization of this significant deal in the burgeoning cannabis industry.